Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

被引：0
|
作者：
Luisa Klotz
Berit Grützke
Maria Eveslage
Michael Deppe
Catharina C. Gross
Lucienne Kirstein
Anita Posevitz-Fejfar
Tilman Schneider-Hohendorf
Nicholas Schwab
Sven G. Meuth
Heinz Wiendl
机构：
[1] University Hospital Münster,Department of neurology
[2] Westfaelische Wilhelms-University Münster,Institute of biostatistics and clinical research
来源：
BMC Neurology | / 15卷
关键词：
Multiple sclerosis; Natalizumab; Fingolimod; PML; Switching;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
    Klotz, Luisa
    Gruetzke, Berit
    Eveslage, Maria
    Deppe, Michael
    Gross, Catharina C.
    Kirstein, Lucienne
    Posevitz-Fejfar, Anita
    Schneider-Hohendorf, Tilman
    Schwab, Nicholas
    Meuth, Sven G.
    Wiendl, Heinz
    BMC NEUROLOGY, 2015, 15
  • [2] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [3] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [4] Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings
    Rinaldi, F.
    Seppi, D.
    Calabrese, M.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (11) : 1640 - 1643
  • [5] Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study
    Tourbah, Ayman
    Papeix, Caroline
    Tourniaire, Patricia
    Rerat, Karin
    Meite, Mohamed
    Durand, Barbara
    Lamy, Fabienne
    Chouette, Isabelle
    Mekies, Claude
    Aboab, Jennyfer
    Al Khedr, Abdullatif
    Carpentier, Amer Al Najjar
    Androdias, Geraldine
    Benrabah, Rabah
    Biotti, Damien
    Bohotin, Valentin
    Bonnan, Mickael
    Bonnet, Cecilia
    Boulesteix, Jean Marc
    Brassat, David
    Busson, Philippe
    Camu, William
    Castelnovo, Giovanni
    Chapuis, Stephane
    Clavelou, Pierre
    Convers, Philippe
    Coustans, Marc
    Creange, Alain
    Delassaux, Sebastien
    Diot, Eric
    Djerdi, Madjid
    Drouet, Thomas
    Delalande, Sophie Dufour
    Pottier, Corinne Dupel
    Ferriby, Didier
    Gaida, Philippe
    Gal, Guillaume
    Giraud, Pierric
    Guilloton, Laurent
    Hascar, Tijani
    Heinzlef, Olivier
    Rouaud, Violaine Jaffrenou
    Jager, Alain
    Kubler, Christophe
    Le Coz, Patrick
    Frenay, Christine Lebrun
    Maillart, Elisabeth
    Vioud, Paris Marcel Maillet
    Malkoun, Imad
    Manchon, Eric
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [6] Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
    Diem, Lara
    Nedeltchev, Krassen
    Kahles, Timo
    Achtnichts, Lutz
    Findling, Oliver
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [7] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia
    Lasalvia, Pieralessandro
    Hernandez, Fabian
    Castaneda-Cardona, Camilo
    Andres Cuestas, J.
    Rosselli, Diego
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 13 - 18
  • [8] Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis
    Grahl, S.
    Bussas, M.
    Wiestler, B.
    Eichinger, P.
    Gaser, C.
    Kirschke, J.
    Zimmer, C.
    Berthele, A.
    Hemmer, B.
    Muehlau, M.
    NEUROTHERAPEUTICS, 2021, 18 (04) : 2589 - 2597
  • [9] Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
    Rodriguez de Castro, Belen
    Martinez-Mugica Barbosa, Cristina
    Ayastuy Ruiz, Aitor
    Fernandez Gonzalez, Beatriz
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (02) : 112 - 114
  • [10] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
12345